CNBC Pro

Eli Lilly obesity drug delivers 20% weight loss, bolstering investment case for new therapies

A woman walks down the street on Michigan Avenue in Chicago, Illinois.
Jeff Haynes | AFP | Getty Images

Clinical trial data released Thursday by Eli Lilly reinforces the belief that a wave of obesity treatments are on the horizon that could be gamechangers for patients struggling to lose weight and perhaps investors as well.

More In Investing trends

CNBC ProPlunging euro to cause some serious earnings trouble for host of U.S. stocks
CNBC Pro‘Dividend aristocrats': Strategists name high-yielding stocks to ride out a bear market
CNBC ProOne boring stock quietly hits all-time high as bear market rages